We are in stealth mode. Contact us to learn more.
Total raised: $6.7M
Investors 1
| Date | Name | Website |
| 10.01.2024 | SeaX Ventu... | seaxventur... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.11.2025 | Seed | $6.7M | Felicis Ve... |
Mentions in press and media 4
| Date | Title | Description |
| 12.11.2025 | Hepta Unveils AI Liquid Biopsy for Chronic Disease | Hepta secures $6.7M. It pioneers AI-driven liquid biopsy for chronic diseases, starting with MASH. Its transformer AI platform analyzes cell-free DNA epigenomes. This delivers unparalleled precision in diagnosis. The non-invasive blood test... |
| 10.11.2025 | Hepta Emerges from Stealth with $6.7M to Pioneer AI-Driven Chronic Disease Liquid Biopsy | What You Should Know: – Hepta, a biotechnology company focused on diagnosing chronic disease, has emerged from stealth announcing $6.7M in seed funding co-led by Felicis Ventures and Illumina Ventures, with participation from SeaX Ventures,... |
| 06.11.2025 | Hepta: $6.7 Million Seed Funding Closed To Advance Liquid Biopsy-Based AI Diagnostics For Chronic Liver Disease | Hepta, a biotechnology company developing a transformer-based artificial intelligence platform to analyze the cell-free DNA epigenome, has emerged from stealth with $6.7 million in seed funding. The round was led by Felicis Ventures and Ill... |
| - | Hepta Bio | “The Future Of Diagnostics, Today” |